Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Clinical trial NCT02242045 · COMPLETED

Trial details

NCT number

NCT02242045

Sponsor

Gilead Sciences

Status

COMPLETED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2014-10-01

Primary completion

2014-12-25

Enrollment

6

View on ClinicalTrials.gov